Cytosorbents Corp

NASDAQ:CTSO  
5.87
-0.12 (-2.00%)
Products

Cytosorbents Gets FDA Investigational Device Exemption Approval For Cardiothoracic Surgery System Trial

Published: 10/12/2021 21:13 GMT
Cytosorbents Corp (CTSO) - Cytosorbents Receives Full FDA Investigational Device Exemption (ide) Approval to Begin U.S. Star-d Trial on Apixaban and Rivaroxaban Removal by the Drugsorb-atr™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery.